The expression levels of PPAR-α/γ and UCP1/2 on the slow coronary flow phenomenon; results from a case-control study.
PPAR-α
PPAR-γ
Reactive oxygen species
Slow coronary flow
UCP1
UCP2
Journal
Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
16
05
2023
accepted:
05
07
2023
medline:
29
8
2023
pubmed:
28
7
2023
entrez:
27
7
2023
Statut:
ppublish
Résumé
The slow coronary flow (SCF) phenomenon is considered a coronary artery disorder. Because of the critical function of peroxisome proliferator-activated receptors (PPARs) in regulating the oxidative stress and inflammatory reactions in cardiovascular disease, The aim of the current study was to investigate the expression of the genes for uncoupling proteins 1 and 2 (UCP1 and UCP2), peroxisome proliferator-activated receptors and (PPAR- PPAR-), and PPAR- in SCF patients. In this case-control study, coronary angiography examination was used to analyze 35 individuals with SCF and 35 subjects with normal coronary flow (NCF). SCF was diagnosed using the TIMI (thrombolysis in myocardial infarction frame count) method. The SCF phenomenon is thought to be the TIMI > 27. In the peripheral blood mononuclear cells (PBMCs), the messenger ribonucleic acid (mRNA) expression levels of the PPAR-, PPAR-, UCP1, and UCP2 genes were evaluated. UCP1 and UCP2 expression levels were significantly higher in the SCF group compared to the NCF group (P = 0.034 and P0.001, respectively). The PPAR- and PPAR- levels were found to be significantly lower in the SCF group compared to the NCF group (P = 0.015, P0.001, respectively). According to the results of the logistic regression analysis, high UCP1 and UCP2 levels and low PPAR- and PPAR- levels are each independent predictors of the SCF phenomenon. This research provided evidence about the potential role of PPAR-α, PPAR-γ, UCP1, and UCP2 as biomarkers in SCF. More investigations are suggested to assess the functions of these factors in SCF patients mechanistically.
Identifiants
pubmed: 37501045
doi: 10.1007/s11033-023-08668-y
pii: 10.1007/s11033-023-08668-y
doi:
Substances chimiques
PPAR gamma
0
UCP1 protein, human
0
Uncoupling Protein 1
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7527-7533Subventions
Organisme : Tabriz University of Medical Sciences
ID : 62278
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Beltrame JF (2012) Defining the coronary slow flow phenomenon. Circ J 76(4):818–820
doi: 10.1253/circj.CJ-12-0205
pubmed: 22374148
Chalikias G, Tziakas D (2021) Slow coronary flow: pathophysiology, clinical implications, and therapeutic management. Angiology 72(9):808–818
doi: 10.1177/00033197211004390
pubmed: 33779300
Enli Y, Turk M, Akbay R, Evrengul H, Tanriverdi H, Kuru O et al (2008) Oxidative stress parameters in patients with slow coronary flow. Adv Ther 25(1):37–44
doi: 10.1007/s12325-008-0011-4
pubmed: 18264683
Hawkins BM, Stavrakis S, Rousan TA, Abu-Fadel M, Schechter E (2012) Coronary slow flow-prevalence and clinical correlations. Circ J 76(4):936–942
doi: 10.1253/circj.CJ-11-0959
pubmed: 22293446
Wang X, Nie S-P (2011) The coronary slow flow phenomenon: characteristics, mechanisms and implications. Cardiovasc Diagn Ther 1(1):37
pubmed: 24282683
pmcid: 3839135
Xia S, Deng S-B, Wang Y, Xiao J, Du J-L, Zhang Y et al (2011) Clinical analysis of the risk factors of slow coronary flow. Heart Vessels 26(5):480–486
doi: 10.1007/s00380-010-0081-5
pubmed: 21207039
Sanati H, Kiani R, Shakerian F, Firouzi A, Zahedmehr A, Peighambari M et al (2016) Coronary slow flow phenomenon clinical findings and predictors. Res Cardiovasc Med 5(1)
Rouzbahani M, Farajolahi S, Montazeri N, Janjani P, Salehi N, Rai A et al (2021) Prevalence and predictors of slow coronary flow phenomenon in Kermanshah province. J Cardiovasc Thorac Res 13: 37–42
Li JJ, Xu B, Li ZC, Qian J, Wei BQ (2006) Is slow coronary flow associated with inflammation? Med Hypotheses 66(3):504–508
doi: 10.1016/j.mehy.2005.09.028
pubmed: 16288834
Danaii S, Shiri S, Dolati S, Ahmadi M, Ghahremani-Nasab L, Amiri A et al (2020) The association between inflammatory cytokines and mirnas with slow coronary flow phenomenon. Iran J Allergy Asthma Immunol 19(1):56–64
pubmed: 32245321
Papathanasiou KA, Vrachatis DA, Deftereos S (2023) Epicardial adipose tissue hyperinflammation might be the broken thread in coronary artery ectasia pathogenesis. Angiology 74(6):600–601
doi: 10.1177/00033197221139690
pubmed: 36357858
Widlansky ME, Gutterman DD (2011) Regulation of endothelial function by mitochondrial reactive oxygen species. Antioxid Redox Signal 15(6):1517–1530
doi: 10.1089/ars.2010.3642
pubmed: 21194353
pmcid: 3151425
Szewczyk A, Jarmuszkiewicz W, Koziel A, Sobieraj I, Nobik W, Lukasiak A et al (2015) Mitochondrial mechanisms of endothelial dysfunction. Pharmacol Rep 67(4):704–710
doi: 10.1016/j.pharep.2015.04.009
pubmed: 26321271
Casteilla L, Rigoulet M, Pénicaud L (2001) Mitochondrial ROS metabolism: modulation by uncoupling proteins. IUBMB Life 52(3–5):181–188
doi: 10.1080/15216540152845984
pubmed: 11798031
Fink BD, Reszka KJ, Herlein JA, Mathahs MM, Sivitz WI (2005) Respiratory uncoupling by UCP1 and UCP2 and superoxide generation in endothelial cell mitochondria. Am J Physiol Endocrinol Metab 288(1):E71–E79
doi: 10.1152/ajpendo.00332.2004
pubmed: 15339748
Madamanchi NR, Runge MS (2007) Mitochondrial dysfunction in atherosclerosis. Circ Res 100(4):460–473
doi: 10.1161/01.RES.0000258450.44413.96
pubmed: 17332437
Mailloux RJ, Harper M-E (2011) Uncoupling proteins and the control of mitochondrial reactive oxygen species production. Free Radical Biol Med 51(6):1106–1115
doi: 10.1016/j.freeradbiomed.2011.06.022
Duval C, Chinetti G, Trottein F, Fruchart J-C, Staels B (2002) The role of PPARs in atherosclerosis. Trends Mol Med 8(9):422–430
doi: 10.1016/S1471-4914(02)02385-7
pubmed: 12223313
Fruchart J, Staels B, Duriez P (2001) PPARS, metabolic disease and atherosclerosis. Pharmacol Res 44(5): 345–352
Kvandova M, Majzúnová M, Dovinová I (2016) The role of PPAR [gamma] in cardiovascular diseases. Physiol Res 65:S343
doi: 10.33549/physiolres.933439
pubmed: 27775420
Neve BP, Fruchart J-C, Staels B (2000) Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. Biochem Pharmacol 60(8):1245–1250
doi: 10.1016/S0006-2952(00)00430-5
pubmed: 11007963
San Cheang W, Tian XY, Wong WT, Huang Y (2015) The peroxisome proliferator-activated receptors in cardiovascular diseases: experimental benefits and clinical challenges. Br J Pharmacol 172(23):5512–5522
doi: 10.1111/bph.13029
Polvani S, Tarocchi M, Galli A (2012) PPARγ and oxidative stress: con(β) catenating NRF2 and FOXO. PPAR Res 2012:641087
doi: 10.1155/2012/641087
pubmed: 22481913
pmcid: 3317010
Tutunchi H, Ostadrahimi A, Saghafi-Asl M, Roshanravan N, Shakeri-Bavil A, Asghari-Jafarabadi M et al (2021) Expression of NF-κB, IL-6, and IL-10 genes, body composition, and hepatic fibrosis in obese patients with NAFLD—combined effects of oleoylethanolamide supplementation and calorie restriction: a triple-blind randomized controlled clinical trial. J Cell Physiol 236(1):417–426
doi: 10.1002/jcp.29870
pubmed: 32572955
Roshanravan N, Shabestari AN, Alamdari NM, Ostadrahimi A, Separham A, Parvizi R et al (2021) A novel inflammatory signaling pathway in patients with slow coronary flow: NF-κB/IL-1β/nitric oxide. Cytokine 143:155511
doi: 10.1016/j.cyto.2021.155511
pubmed: 33839001
Binak E, Gunduz H, Sahin M, Kurtoglu N, Dindar I (2006) The relation between impaired glucose tolerance and slow coronary flow. Int J Cardiol 111(1):142–146
doi: 10.1016/j.ijcard.2005.09.007
pubmed: 16297474
Gibson CM, Cannon CP, Daley WL, Dodge JT Jr, Alexander B, Marble SJ et al (1996) TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 93(5):879–888
doi: 10.1161/01.CIR.93.5.879
pubmed: 8598078
Zhu X, Shen H, Gao F, Wu S, Ma Q, Jia S et al (2019) Clinical profile and outcome in patients with coronary slow flow phenomenon. Cardiol Res Pract 2019:9168153
doi: 10.1155/2019/9168153
pubmed: 31205785
pmcid: 6530115
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2
Javadi DH, Sotudeh DS, Javadi DA, Rezaee DM, Hajikarimi DM (2022) Echocardiographic evaluation of left and right ventricular function in patients with coronary slow flow syndrome: a comparative study. Curr Probl Cardiol 47(9):100925
doi: 10.1016/j.cpcardiol.2021.100925
pubmed: 34364691
Cadenas S (2018) Mitochondrial uncoupling, ROS generation and cardioprotection. Biochimica et Biophysica Acta (BBA) Bioenerget 1859(9): 940–950
Brand MD, Esteves TC (2005) Physiological functions of the mitochondrial uncoupling proteins UCP2 and UCP3. Cell Metab 2(2):85–93
doi: 10.1016/j.cmet.2005.06.002
pubmed: 16098826
Moukdar F, Robidoux J, Lyght O, Pi J, Daniel KW, Collins S (2009) Reduced antioxidant capacity and diet-induced atherosclerosis in uncoupling protein-2-deficient mice. J Lipid Res 50:59
doi: 10.1194/jlr.M800273-JLR200
pubmed: 18698091
Koziel A, Sobieraj I, Jarmuszkiewicz W (2015) Increased activity of mitochondrial uncoupling protein 2 improves stress resistance in cultured endothelial cells exposed in vitro to high glucose levels. Am J Physiol Heart Circulat Physiol 309(1):H147–H156
doi: 10.1152/ajpheart.00759.2014
Small DM, Morais C, Coombes JS, Bennett NC, Johnson DW, Gobe GC (2014) Oxidative stress-induced alterations in PPAR-γ and associated mitochondrial destabilization contribute to kidney cell apoptosis. Am J Physiol Renal Physiol 307(7):F814–F822
doi: 10.1152/ajprenal.00205.2014
pubmed: 25122050
Lee TI, Kao YH, Chen YC, Chen YJ (2009) Proinflammatory cytokine and ligands modulate cardiac peroxisome proliferator-activated receptors. Eur J Clin Invest 39(1):23–30
doi: 10.1111/j.1365-2362.2008.02062.x
pubmed: 19067734
Lee TI, Kao YH, Chen YC, Pan NH, Chen YJ (2010) Oxidative stress and inflammation modulate peroxisome proliferator-activated receptors with regional discrepancy in diabetic heart. Eur J Clin Invest 40(8):692–699
doi: 10.1111/j.1365-2362.2010.02318.x
pubmed: 20561028
Mahmoud AM, Alexander MY, Tutar Y, Wilkinson FL, Venditti A (2017) Oxidative stress in metabolic disorders and drug-induced injury: the potential role of Nrf2 and PPARs activators. Oxid Med Cell Longev 2017:2508909
doi: 10.1155/2017/2508909
pubmed: 29348787
pmcid: 5733955